Amalgamated Bank raised its position in shares of BIO-TECHNE Corp (NASDAQ:TECH) by 5.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 7,772 shares of the biotechnology company’s stock after purchasing an additional 399 shares during the quarter. Amalgamated Bank’s holdings in BIO-TECHNE were worth $1,007,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Advisory Services Network LLC lifted its position in shares of BIO-TECHNE by 1,423.3% in the 4th quarter. Advisory Services Network LLC now owns 1,112 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 1,039 shares during the period. Zions Bancorporation purchased a new stake in shares of BIO-TECHNE in the 3rd quarter worth about $178,000. Gofen & Glossberg LLC IL purchased a new stake in shares of BIO-TECHNE in the 4th quarter worth about $205,000. Aull & Monroe Investment Management Corp purchased a new stake in shares of BIO-TECHNE in the 4th quarter worth about $214,000. Finally, Turner Investments LLC purchased a new stake in shares of BIO-TECHNE in the 3rd quarter worth about $242,000. 97.15% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

BIO-TECHNE Corp (NASDAQ:TECH) opened at $146.82 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.10 and a quick ratio of 2.49. The stock has a market cap of $5,500.00, a PE ratio of 66.74, a P/E/G ratio of 2.81 and a beta of 0.75. BIO-TECHNE Corp has a 12 month low of $98.22 and a 12 month high of $148.26.

BIO-TECHNE (NASDAQ:TECH) last issued its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.10. The company had revenue of $154.15 million during the quarter, compared to analyst estimates of $145.93 million. BIO-TECHNE had a net margin of 19.17% and a return on equity of 14.39%. BIO-TECHNE’s quarterly revenue was up 16.9% compared to the same quarter last year. During the same period last year, the business earned $0.81 EPS. analysts anticipate that BIO-TECHNE Corp will post 4.01 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, March 2nd. Investors of record on Friday, February 16th were paid a $0.32 dividend. The ex-dividend date of this dividend was Thursday, February 15th. This represents a $1.28 annualized dividend and a dividend yield of 0.87%. BIO-TECHNE’s payout ratio is 58.18%.

Several equities research analysts have recently commented on the stock. Deutsche Bank set a $163.00 target price on shares of BIO-TECHNE and gave the stock a “buy” rating in a research report on Thursday, March 1st. Zacks Investment Research raised shares of BIO-TECHNE from a “hold” rating to a “buy” rating and set a $158.00 target price for the company in a research report on Saturday, January 20th. Robert W. Baird reaffirmed a “buy” rating and issued a $154.00 target price on shares of BIO-TECHNE in a research report on Thursday, January 18th. Craig Hallum reaffirmed a “buy” rating and issued a $160.00 target price (up from $140.00) on shares of BIO-TECHNE in a research report on Wednesday, February 7th. Finally, BidaskClub raised shares of BIO-TECHNE from a “hold” rating to a “buy” rating in a research report on Wednesday, January 10th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $148.60.

In related news, Director Charles A. Dinarello sold 5,000 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $136.06, for a total value of $680,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.40% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2018/03/15/amalgamated-bank-has-1-01-million-holdings-in-bio-techne-corp-tech.html.

About BIO-TECHNE

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BIO-TECHNE Corp (NASDAQ:TECH).

Institutional Ownership by Quarter for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.